Logo image of MGLN

MAGELLAN HEALTH INC (MGLN) Stock Fundamental Analysis

NASDAQ:MGLN - Nasdaq - Common Stock

94.99  0 (0%)

After market: 94.99 0 (0%)

Fundamental Rating

2

Overall MGLN gets a fundamental rating of 2 out of 10. We evaluated MGLN against 108 industry peers in the Health Care Providers & Services industry. The financial health of MGLN is average, but there are quite some concerns on its profitability. MGLN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MGLN was profitable.
MGLN Yearly Net Income VS EBIT VS OCF VS FCFMGLN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 100M 200M 300M

1.2 Ratios

Industry RankSector Rank
ROA 9%
ROE 15.61%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MGLN Yearly ROA, ROE, ROICMGLN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 5 10 15 20

1.3 Margins

Industry RankSector Rank
OM 1.03%
PM (TTM) 6.26%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MGLN Yearly Profit, Operating, Gross MarginsMGLN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2 4 6 8

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, MGLN has more shares outstanding
The debt/assets ratio for MGLN has been reduced compared to a year ago.
MGLN Yearly Shares OutstandingMGLN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 5M 10M 15M 20M 25M
MGLN Yearly Total Debt VS Total AssetsMGLN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 1B 2B 3B

2.2 Solvency

MGLN has an Altman-Z score of 3.80. This indicates that MGLN is financially healthy and has little risk of bankruptcy at the moment.
MGLN has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Altman-Z 3.8
ROIC/WACCN/A
WACCN/A
MGLN Yearly LT Debt VS Equity VS FCFMGLN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 500M 1B 1.5B

2.3 Liquidity

MGLN has a Current Ratio of 2.92. This indicates that MGLN is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 2.86 indicates that MGLN has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 2.92
Quick Ratio 2.86
MGLN Yearly Current Assets VS Current LiabilitesMGLN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 500M 1B 1.5B 2B

More info and screens

4

3. Growth

3.1 Past

MGLN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -67.07%.
The Earnings Per Share has been growing slightly by 6.05% on average over the past years.
MGLN shows a small growth in Revenue. In the last year, the Revenue has grown by 6.52%.
MGLN shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.09% yearly.
EPS 1Y (TTM)-67.07%
EPS 3Y-32.6%
EPS 5Y6.05%
EPS Q2Q%-62.5%
Revenue 1Y (TTM)6.52%
Revenue growth 3Y-7.79%
Revenue growth 5Y-0.09%
Sales Q2Q%7.18%

3.2 Future

The Earnings Per Share is expected to grow by 42.68% on average over the next years. This is a very strong growth
Based on estimates for the next years, MGLN will show a small growth in Revenue. The Revenue will grow by 7.97% on average per year.
EPS Next Y11.05%
EPS Next 2Y43.46%
EPS Next 3Y36.35%
EPS Next 5Y42.68%
Revenue Next Year8.27%
Revenue Next 2Y8.12%
Revenue Next 3Y8.38%
Revenue Next 5Y7.97%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MGLN Yearly Revenue VS EstimatesMGLN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B
MGLN Yearly EPS VS EstimatesMGLN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2 4 6 8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 87.15, the valuation of MGLN can be described as expensive.
MGLN is valuated expensively when we compare the Price/Earnings ratio to 29.62, which is the current average of the S&P500 Index.
MGLN is valuated quite expensively with a Price/Forward Earnings ratio of 27.31.
MGLN is valuated rather expensively when we compare the Price/Forward Earnings ratio to 22.70, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 87.15
Fwd PE 27.31
MGLN Price Earnings VS Forward Price EarningsMGLN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 12.26
MGLN Per share dataMGLN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 50 100 150

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
MGLN's earnings are expected to grow with 36.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)7.88
PEG (5Y)14.41
EPS Next 2Y43.46%
EPS Next 3Y36.35%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MGLN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MAGELLAN HEALTH INC

NASDAQ:MGLN (1/3/2022, 8:23:03 PM)

After market: 94.99 0 (0%)

94.99

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A N/A
Earnings (Next)03-04 2022-03-04/amc
Inst Owners1.27%
Inst Owner Change0%
Ins Owners1.57%
Ins Owner Change0%
Market Cap2.46B
Analysts43.33
Price Target96.9 (2.01%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 87.15
Fwd PE 27.31
P/S 0.51
P/FCF N/A
P/OCF N/A
P/B 1.27
P/tB N/A
EV/EBITDA 12.26
EPS(TTM)1.09
EY1.15%
EPS(NY)3.48
Fwd EY3.66%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS186.23
BVpS74.7
TBVpSN/A
PEG (NY)7.88
PEG (5Y)14.41
Profitability
Industry RankSector Rank
ROA 9%
ROE 15.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 1.03%
PM (TTM) 6.26%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover1.44
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.92
Quick Ratio 2.86
Altman-Z 3.8
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-67.07%
EPS 3Y-32.6%
EPS 5Y6.05%
EPS Q2Q%-62.5%
EPS Next Y11.05%
EPS Next 2Y43.46%
EPS Next 3Y36.35%
EPS Next 5Y42.68%
Revenue 1Y (TTM)6.52%
Revenue growth 3Y-7.79%
Revenue growth 5Y-0.09%
Sales Q2Q%7.18%
Revenue Next Year8.27%
Revenue Next 2Y8.12%
Revenue Next 3Y8.38%
Revenue Next 5Y7.97%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A